Amedica Corporation 3D Prints Silicon Nitride for Medical Applications

Emerging Technology

Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, has 3D printed complex, three-dimensional structures through a process called robotic deposition, or robocasting.

Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, has 3D printed complex, three-dimensional structures through a process called robotic deposition, or robocasting.
According to the press release:

The final products have been examined under scanning electron microscopy to confirm the integrity and validity of the 3D printing method, and have been shown to achieve similar theoretical density and microstructure attributes to the traditionally manufactured silicon nitride fusion devices currently in use.
“This innovation speaks to the unique art and science related to our manufacturing strength,” said Dr. Sonny Bal, Chairman and Chief Executive Officer. “3D printing of a complex ceramic material opens future doors, especially in terms of cost advantages, and addressing a variety of OEM partner needs. Custom additive manufacturing is a modern advancement, and we are proud to lead the way in 3D printing of our silicon nitride formulation, with its advantages in bone fusion, antibacterial behavior, and superior strength.”
Robocasting is a freeform fabrication technique for dense ceramics and composites that is based on layered deposition of highly colloidal slurries. The process is essentially binder-less and a device can be completely sintered in less than 24 hours. With this advancement, Amedica can now progress toward commercializing 3D printed silicon nitride implants, with controllable porosity levels to address specific clinical needs. This unique manufacturing method is promising for the production of anatomically relevant shaped silicon nitride implants, while also allowing custom fabrication of bone scaffolds suited for cellular differentiation and neovascularization.

Click here to read the full press release.


 
The Conversation (0)
×